Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients. Academic Article uri icon



  • PURPOSE: To study a commonly used Astragalus-based herbal formula previously found effective in non-small cell lung cancer (NSCLC) on the pharmacokinetics of docetaxel in patients with NSCLC. METHODS: Patients with advanced NSCLC who progressed after prior platinum-containing chemotherapy were accrued and received docetaxel at 35 mg/m(2) for 3 weeks followed by 1 week of rest. At 4 days prior to the second dosing, Jinfukang was given orally. Pharmacokinetic studies of initial-dose docetaxel (in the absence of Jinfukang) and the third dose (in the presence of Jinfukang) were compared. RESULTS: Of the 24 patients enrolled, 21 started Jinfukang and docetaxel. Jinfukang had no significant impact on the pharmacokinetics of docetaxel. Median time to progression or withdrawal from treatment was 7 weeks. Twelve patients were removed from study for progression of disease; nine patients withdrew. CONCLUSIONS: Jinfukang did not alter the pharmacokinetics of docetaxel nor appear to affect survival in this study.

publication date

  • May 7, 2009



  • Antineoplastic Agents
  • Carcinoma, Non-Small-Cell Lung
  • Drugs, Chinese Herbal
  • Lung Neoplasms
  • Plant Extracts
  • Taxoids


PubMed Central ID

  • PMC3746541

Scopus Document Identifier

  • 70349624128

Digital Object Identifier (DOI)

  • 10.1007/s00280-009-1003-z

PubMed ID

  • 19421753

Additional Document Info


  • 65


  • 1